

---

# Index

---

- ε-aminocaproic acid, 134f
- anaphylatoxin inactivator, 235
- anaphylatoxins, 233ff
- anaphylatoxins, cellular responses to, 234
- angiotensin-converting enzyme, in
  - inactivation of kinins, 244f
- angiotensinogen, structure of, 294, 369
- α<sub>1</sub>-antichymotrypsin, structure of, 291, 369
- antithrombin III
  - genetic defects in, 108
  - heparin-binding site of, 107
  - rôle in blood coagulation, 105f
  - structure of, 106f, 318
- apolipoprotein (a), structure of, 138ff
  
- blood coagulation, 3ff
  - other mechanisms of inhibition, 126f
  - proteins of, 4
  - regulation by proteolytic inactivation, 110ff
  - regulation of, 104ff
  - survey of, 5
- bradykinin, 15, 243
  
- [(C1r)<sub>2</sub>(C1s)<sub>2</sub>], structure of, 174ff
- C1<sup>-</sup>-inhibitor
  - genetic defects in, 215
  - mechanism of inhibition of C1<sup>-</sup>, 215f
  - rôle in blood coagulation, 105f
  - structure of, 214f, 342
- C3 convertase
  - decay of, 226
  - formation of in alternative activation pathway, 197f
  - formation of in classical activation pathway, 188
  - in classical activation pathway, 186f
  - initial formation of in alternative activation pathway, 196f
  - proteolytic inactivation of, 227f
  - stabilisation by properdin, 228f
- C4b-binding protein
  - complex with protein S, 120, 122, 125, 219
  - structure of, 217ff, 344
- C5-convertase
  - formation of in alternative activation pathway, 198f
  - formation of in classical activation pathway, 189
- carbohydrate
  - asparagine-bound, 246f
  - mechanism of attachment to Asn residues, 246ff
  - serine- and threonine-bound, 246ff
- γ-carboxyglutamic acid
  - in factor VII, 72
  - in factor IX, 26
  - in factor X, 48
  - in protein C, 112
  - in protein S, 121
  - in prothrombin, 62
- γ-carboxylation of Glu residues, 252ff
  - mechanism of, 252ff
  - signal for, 254ff
- carboxypeptidase N
  - in inactivation of kinins, 244f
  - structure of, 235f, 349
- ceruloplasmin, 38f
- coagulation-active surfaces, 259ff
  - Gla-dependent binding to, 266f
  - protein binding to, 265ff
- complement component C1
  - activation of, 176ff
  - structure of, 166ff, 174ff
- complement component C1q
  - genetic defects in, 169
  - 5-hydroxylysine in, 169
  - 4-hydroxyproline in, 169
  - structure of, 166ff, 328
- complement component C1r
  - autolytic fragments of, 174f

464 *Index*

- complement component C1s (*cont.*)  
 homology with complement component C1s, 173  
 structure of, 169ff, 329
- complement component C1s  
 homology with complement component C1r, 173  
 structure of, 171ff, 330
- complement component C2  
 activation of, 186  
 homology with complement factor B, 194  
 structure of, 179ff, 331
- complement component C3  
 activation of, 187  
 genetic variant of, 182f  
 structure of, 182f, 334f  
 thioester in, 182
- complement component C3(H<sub>2</sub>O), 196
- complement component C3b  
 reaction pathways of, 188  
 reactivity of thioester in, 187
- complement component C4  
 activation of, 186  
 polymorphism of, 184f  
 structure of, 183ff, 334f  
 thioester in, 185  
 tyrosine-*O*-sulphate in, 185
- complement component C4b  
 reaction pathways of, 187  
 reactivity of thioester in, 186
- complement component C5, structure of, 201f, 337
- complement component C6, structure of, 202f, 338
- complement component C7, structure of, 202f, 339
- complement component C8, structure of, 203ff, 340f
- complement component C9, structure of, 209f, 342
- complement factor B  
 homology with complement component C2, 194  
 structure of, 192f, 336
- complement factor D, structure of, 191f, 335
- complement factor H, structure of, 217, 343
- complement receptor type 1 (CR1)  
 function of, 237f  
 long homologous repeats in, 224  
 structure of, 223ff, 345f
- complement receptor type 2 (CR2)  
 long homologous repeats in, 239  
 structure of, 238f, 350
- complement receptor type 3 (CR3), structure of, 240, 351f
- complement receptors, 237ff
- complement system, 163ff  
 activators of alternative pathway, 195  
 alternative activation pathway of, 191ff  
 classical activation pathway of, 166ff  
 components of, 164f  
 mechanism of alternative activation pathway, 195ff  
 membrane attack complex, 201ff  
 regulation of, 214ff  
 survey of the alternative activation pathway, 200  
 survey of the classical activation pathway, 190
- contact activation, 6ff  
 mechanism of, 19, 21ff  
 proteins of, 6ff
- corticosteroid-binding globulin, structure of, 293, 370
- decay-accelerating factor (DAF)  
 anchoring to membranes, 221ff  
 structure of, 221ff, 344  
 degree of identity, definition of, xiv
- endothelium, rôle in blood coagulation, 262ff
- evolution of protein structures, 295ff
- exon-shuffling, 297ff
- extrinsic pathway  
 activation processes of, 75ff  
 components of, 71ff
- extrinsic pathway inhibitor  
 mechanism of action, 110  
 structure of, 107ff, 318
- factor I  
 domains in heavy chain, 227  
 structure of, 226f, 347
- factor I-like domains, in complement components C6 and C7, 207, 209
- factor V  
 homology with factor VIII, 56ff  
 structure of, 54ff, 310f  
 tyrosine-*O*-sulphate in, 56
- factor V/Va, binding to phospholipid, 65f
- factor Va  
 interaction with factor Xa, 65  
 proteolytic inactivation of, 122ff  
 structure of, 56ff
- factor VII  
 enzyme activity of, 76f  
 structure of, 71ff, 313
- factor VII/VIIa, interaction with tissue factor, 75
- factor VIII  
 genetic defects in, 45ff  
 homology with factor V, 56ff  
 interaction with von Willebrand factor, 36, 43f, 274

- structure of, 36ff, 307f
  - tyrosine-*O*-sulphate in, 41
- factor VIII/VIIIa, binding to phospholipid, 51
- factor VIIIa
  - interaction with factor IXa, 50f
  - proteolytic inactivation of, 122ff
  - structure of, 41f, 50
- factor IX
  - activation of, 32ff
  - genetic defects in, 27ff
  - high-affinity  $\text{Ca}^{2+}$ -binding site, 33
  - structure of, 25ff, 306
- factor IXa
  - function of Gla residues, 49f
  - interaction with factor VIIIa, 50f
  - structure of, 49
- factor X
  - activation of, 49ff
  - genetic defects in, 49
  - interaction with Xase enzyme complex, 53
  - structure of, 45ff, 309
  - tyrosine-*O*-sulphate in, 48
- factor Xa
  - function of Gla residues, 64
  - interaction with factor Va, 65
  - structure of, 64
- factor XI
  - genetic defects in, 12
  - homology with plasma prekallikrein, 11, 13
  - interaction with HMM-kininogen, 19ff
  - structure of, 10ff, 304
- factor XIa, inhibition by  $\alpha_1$ -proteinase inhibitor, 106
- factor XII
  - genetic defects in, 8
  - structure of, 6ff, 302
- factor XIIa, inhibition by  $\text{C}\bar{\text{I}}$ -inhibitor, 106
- factor XIII
  - activation of, 98f
  - N*-acetyl serine in, 89
  - SCR domains in, 90f
  - structure of, 88ff, 316f
- factor XIIIa, mechanism of action, 98ff
- fibrin
  - degradation by plasmin, 153ff
  - formation of, 80ff
  - stabilisation of, 80ff
- fibrin formation, 80ff
  - mechanism of, 90ff
  - polymerisation sites in, 94ff
  - release of fibrinopeptide A in, 94
  - release of fibrinopeptide B in, 96
- fibrin stabilisation, mechanism of, 97ff
- fibrinogen
  - genetic defects in, 88
  - phospho-*O*-serine in, 81
  - structure of, 80ff, 314f
  - tyrosine-*O*-sulphate in, 84
- fibrinolysis, 131ff
  - mechanisms in, 149ff
  - regulation of, 156ff
- fibrinolytic system
  - components of, 132
  - survey of, 159
- fibronectin
  - domain structure of, 276
  - phospho-*O*-serine in, 275
  - R-G-D in, 275
  - structure of, 275, 356f
- fibronectin receptor (VLA-5), structure of, 284, 362f
- fibronectin type I domain
  - in factor XII, 7f
  - in tissue plasminogen activator, 144
  - standard domain element, xv
- fibronectin type II domain
  - in factor XII, 7
  - standard domain element, xv
- Gla domain, in factor VII, 72
  - in factor IX, 26f
  - in factor X, 48
  - in protein C, 112f
  - in protein S, 121
  - in prothrombin, 62
  - standard domain element, xv
- glycoprotein Ib
  - fatty-acid esterification of, 278
  - interaction with von Willebrand factor, 278
  - phospho-*O*-serine in, 278
  - structure of, 276ff, 359
- glycoprotein IIb, structure of, 278ff, 360
- glycoprotein IIb-IIIa
  - binding of fibrinogen to, 271
  - binding of proteins to, 271
  - structure of, 278ff
- glycoprotein IIIa, structure of, 281f, 361
- glycoprotein IX
  - fatty-acid esterification of, 278
  - structure of, 278, 360
- glycosylation, 246ff
- growth-factor domain
  - in complement component C1r, 170
  - in complement component C1s, 172
  - in tissue plasminogen activator, 144
  - in urokinase, 142
  - standard domain element, xv
- growth-factor domains
  - in complement components C6, C7, C8 $\alpha$ , C8 $\beta$  and C9, 207
  - in factor VII, 72
  - in factor IX, 27
  - in factor X, 48
  - in factor XII, 7

466 *Index*

- growth-factor domains (*cont.*)  
 in protein C, 113  
 in protein S, 121  
 in thrombomodulin, 115
- haemophilia A, 45ff  
 haemophilia B, 27ff  
 haemostasis, 269ff  
 rôle of fibrinogen, 270ff  
 rôle of glycoprotein Ib, 270ff  
 rôle of glycoprotein IIb–IIIa, 270ff  
 rôle of thrombospondin, 271f  
 rôle of von Willebrand factor, 270ff
- Hageman factor, 6ff  
 heparin co-factor II  
 structure of, 291ff, 368  
 tyrosine-*O*-sulphate in, 292
- histidine-rich glycoprotein, in fibrinolysis, 158
- HMM-kininogen  
 as cysteine-protease inhibitor, 16f  
 interaction with factor XI, 19ff  
 interaction with plasma prekallikrein, 19ff  
 structure of, 14ff, 305
- homologous restriction, 231f  
 homologous restriction factor, 231
- $\beta$ -hydroxyasparagine  
 in complement component C1r, 171  
 in complement component C1s, 172  
 in protein S, 121
- $\beta$ -hydroxyaspartic acid  
 in binding of  $\text{Ca}^{2+}$ , 267f  
 in factor VII, 72  
 in factor IX, 27, 33f  
 in factor X, 48  
 in protein C, 113  
 in protein S, 121  
 in thrombomodulin, 120
- $\beta$ -hydroxylation of Asp and Asn residues, 258
- IA domains  
 in complement component C1r, 170  
 in complement component C1s, 172
- integrins, 283ff
- kallidin, 243  
 kinin system, 243ff  
 kininogen, T, *see* T-kininogen  
 kinins  
 inactivation of, 244f  
 structure of, 243
- kringle domain  
 in factor XII, 8  
 in urokinase, 142  
 standard domain element, xv
- kringle domains  
 in apolipoprotein (a), 139ff  
 in plasminogen, 133  
 in prothrombin, 62f  
 in tissue plasminogen activator, 144
- LDL-receptor domains, in complement components C6, C7, C8 $\alpha$ , C8 $\beta$  and C9, 207
- LFA-1, structure of, 285, 365  
 LMM-kininogen, 16  
 lysine analogues, 134f
- meizothrombin, 66ff  
 membrane attack complex  
 formation of, 210ff  
 model of, 212  
 regulation of, 229ff  
 membrane co-factor protein (MCP), structure of, 225f, 347  
 modification of amino-acid residues, 252ff
- ovalbumin, structure of, 371
- p150,95, structure of, 285f, 366  
 PAI-1, structure of, 146f, 326  
 PAI-2, structure of, 147f, 327  
 phospholipid, 35ff  
 plasma kallikrein  
 inhibition by C1-inhibitor, 106  
 interaction with HMM-kininogen, 19ff  
 structure of, 8ff, 303
- $\alpha_2$ -plasmin inhibitor  
 genetic defects in, 145f  
 interaction with plasminogen, 157f  
 structure of, 145f, 326  
 tyrosine-*O*-sulphate in, 145
- plasminogen  
 activation of, 152f  
 binding of fibrin(ogen), 137f  
 genetic defects in, 138  
 interaction with  $\alpha_2$ -plasmin inhibitor, 157f  
 lysine-binding sites in, 135ff  
 structure of, 131ff, 323
- platelets, rôle in blood coagulation, 259ff  
 prekallikrein/factor XI domain, standard domain element, xv  
 prekallikrein/factor XI domains  
 in factor XI, 11, 14  
 in plasma prekallikrein, 9f  
 properdin, structure of, 228f, 348  
 protease nexin, structure of, 148, 327
- protein C  
 activation of, 114ff  
 genetic defects in, 114  
 structure of, 110ff, 319
- protein Ca, complex with protein S, 123  
 protein Ca inhibitor, structure of, 126, 322
- protein S  
 complex with C4b-binding protein, 120,

- 122, 125, 219  
 complex with protein Ca, 123  
 genetic defects in, 122  
 structure of, 120ff, 321  
 protein secretion, 250ff  
 $\alpha_1$ -proteinase inhibitor  
 genetic defects in, 291f  
 rôle in blood coagulation, 105f  
 structure of, 290f, 368  
 prothrombin  
 activation of, 64ff  
 genetic defects in, 64  
 structure of, 61ff, 312  
 prothrombinase enzyme complex  
 choice of substrate, 69f  
 components of, 54ff  
 formation of, 66  
 mechanism of action, 66ff  
 structure of, 64ff  
 pro-urokinase, affinity for fibrin, 150
- S-protein  
 functions of, 230f  
 phospho-O-serine in, 230  
 R-G-D in, 230  
 structure of, 229f, 348  
 tyrosine-O-sulphate in, 230
- SCR domain, standard domain element, xv  
 SCR domains  
 in C4b-binding protein, 218  
 in complement component C1r, 170  
 in complement component C1s, 172  
 in complement component C2, 181  
 in complement components C6 and C7, 207, 209  
 in complement factor B, 192  
 in complement factor H, 217  
 in complement receptor type 1, 224  
 in complement receptor type 2, 238f  
 in decay-accelerating factor, 222  
 in membrane co-factor protein, 225  
 serine-protease domain, standard domain element, xv  
 serine-protease inhibitor, mechanism of action, 105  
 serpins, 287ff  
 tables of, 288f  
 signal peptides, 249ff  
 signal/propeptide, 254ff  
 SP-40,40, 231  
 T-kininogen, 18f
- thrombin, inhibition by antithrombin III, 106  
 thrombomodulin  
 phospho-O-serine in, 115  
 structure of, 114ff, 320  
 thrombospondin  
 domain structure of, 276  
 R-G-D in, 276  
 structure of, 275f, 358  
 thrombospondin type I domains, in complement components C6, C7, C8 $\alpha$ , C8 $\beta$  and C9, 207ff  
 thyroxine-binding globulin, structure of, 293, 370  
 tissue factor  
 fatty-acid esterification of, 75  
 interaction with factor VII/VIIa, 75  
 structure of, 73ff, 313  
 tissue plasminogen activator (t-PA)  
 affinity for fibrin, 150f  
 domains interacting with fibrin, 151  
 structure of, 143ff, 325  
 tranexamic acid, 134f
- urokinase  
 activation of, 149f  
 structure of, 142f, 324  
 urokinase receptor, 150
- vitronectin receptor, structure of, 286, 367  
 VLA-2, structure of, 285, 364  
 von Willebrand antigen II, 273  
 R-G-D in, 273  
 von Willebrand factor  
 domain structure of, 273f  
 interaction with factor VIII, 274  
 interaction with glycoprotein Ib, 274  
 interaction with glycoprotein IIb-IIIa, 274  
 R-G-D in, 273  
 structure of, 272ff, 353ff  
 sulphation of, 273  
 von Willebrand factor A domains  
 in complement component C2, 181  
 in complement factor B, 192
- Xase enzyme complex  
 choice of substrate, 51f  
 components of, 35ff  
 interaction with factor X, 53  
 mechanism of action, 51ff  
 structure of, 51f